Is It Possible for Genetic Mutations in MPNs to Affect Treatment Choices?

MPN expert Dr. Rami Komrokji of Moffitt Cancer Center discusses various genetic marker subsets of myeloproliferative neoplasms (MPNs) and how these alterations affect what type of treatment a patient should receive. Dr. Komrokji points out that genetic testing allows doctors to make a firm diagnosis and choose different courses of treatment.

Get email alerts | http://www.patientpower.info/alerts

Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo